BioCryst Pharmaceuticals, Inc.

565 articles about BioCryst Pharmaceuticals, Inc.

• BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO®

  11/5/2021

  BioCryst Pharmaceuticals, Inc. today announced new long-term efficacy and safety data from studies evaluating oral, once-daily ORLADEYO ®  

• BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones

  11/3/2021

  BioCryst Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 02, 2021

  11/2/2021

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 95,500 shares of BioCryst common stock on October 29, 2021 as inducements material to each employee entering into employment with BioCryst.

• BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer

  11/1/2021

  BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the appointment of Jinky Ang Rosselli as chief data and insights officer.

• BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

  10/26/2021

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts, including one Distinguished Industry Oral Abstract, on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI).

• BioCryst to Report Third Quarter 2021 Financial Results on November 3

  10/20/2021

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2021 financial results on Wednesday, November 3, 2021.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 04, 2021

  10/4/2021

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 178,500 shares of BioCryst common stock on September 30, 2021 as inducements material to each employee entering into employment with BioCryst.

• 

  BioSpace Movers & Shakers, Sept. 24

  9/24/2021

  Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• BioCryst to Present at 2021 Cantor Virtual Healthcare Conference

  9/21/2021

  BioCryst Pharmaceuticals, Inc. announced that the company will present at the 2021 Cantor Virtual Healthcare Conference on Tuesday, September 28, 2021 at 2:00 p.m. ET.

• BioCryst Appoints Dr. Amy McKee to Board of Directors

  9/20/2021

  BioCryst Pharmaceuticals, Inc. announced that the company has appointed regulatory expert and former deputy center director of the U.S. Food and Drug Administration Oncology Center of Excellence, Amy McKee, M.D., to its board of directors.

• NICE Recommends BioCryst’s ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK

  9/16/2021

  BioCryst Pharmaceuticals, Inc. announced that the United Kingdom’s National Institute for Health and Care Excellence has recommended ORLADEYO® for preventing recurrent attacks of hereditary angioedema in eligible patients 12 years and older if they have at least two attacks per month.

• BioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates

  9/9/2021

  BioCryst Pharmaceuticals, Inc. announced that the Ministry of Health and Prevention in the United Arab Emirates has granted marketing authorization for oral, once-daily ORLADEYO® for the prevention of recurrent attacks in patients with hereditary angioedema 12 years and older.

• BioCryst to Present at Upcoming Investor Conferences in September 2021

  9/3/2021

  BioCryst Pharmaceuticals, Inc. announced that the company will present at the 2021 Virtual Wells Fargo Healthcare Conference on Friday, September 10, 2021 at 1:20 p.m. ET and at the H.C. Wainwright 23rd Annual Global Investment Conference.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 02, 2021

  9/2/2021

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 18 newly-hired employees inducement options to purchase an aggregate of 199,000 shares of BioCryst common stock on August 31, 2021 and September 1, 2021 as inducements material to each employee entering into employment with BioCryst.

• U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile

  9/1/2021

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst’s antiviral influenza therapy, RAPIVAB® (peramivir injection), for approximately $7 million.

• BioCryst Appoints Dr. Steven Galson to Board of Directors

  8/26/2021

  BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed former director of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), and former acting surgeon general, Steven Galson, M.D., MPH to its board of directors.

• BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic

  8/25/2021

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the new drug submission for ORLADEYO® (berotralstat) has been accepted for review by Health Canada for the prevention of recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older.

• 

  BioCryst Pharma Cancels Planned Public Offering, Says Funds Are Sufficient

  8/11/2021

  The global biopharmaceutical company said that it is well capitalized with cash, cash equivalents, restricted cash, and investments of as much as $222.8 million as of 30 June 2021.

• BioCryst Withdraws Public Offering - Aug 10, 2021

  8/10/2021

  BioCryst Pharmaceuticals, Inc. announced that it has withdrawn its proposed public offering.

• BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants - Aug 09, 2021

  8/9/2021

  BioCryst Pharmaceuticals, Inc. announced that it is offering to sell $200 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering.